Francesc Mitjans

Dr. Francesc Mitjans

Health & Biomedicine Department. LEITAT Technological Center. @ Parc Científic de Barcelona. Baldiri Reixac, 15. 08028 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JHJose Luis Hernández
Jose Luis Hernández
LPLaura Padilla
Laura Padilla
SDSheila Dakhel
Sheila Dakhel
TCToni Coll
Toni Coll
RHRosa Hervas
Rosa Hervas
RMRamon Messeguer
Ramon Messeguer
S100A4, a member of the S100 calcium-binding protein family secreted by tumor and stromal cells, supports tumorigenesis by stimulating angiogenesis. We demonstrated that S100A4 synergizes with vascular endothelial growth factor (VEGF), via the RAGE receptor, in promoting endothelial cell migration by increasing KDR expression and MMP-9 activity. In vivo overexpression of S100A4 led to a significant increase in tumor growth and vascularization in a human melanoma xenograft M21 model. Conversely, when silencing S100A4 by shRNA technology, a dramatic decrease in tumor development of the pancreatic MiaPACA-2 cell line was observed. Based on these results we developed 5C3, a neutralizing monoclonal antibody against S100A4. This antibody abolished endothelial cell migration, tumor growth and angiogenesis in immunodeficient mouse xenograft models of MiaPACA-2 and M21-S100A4 cells. It is concluded that extracellular S100A4 inhibition is an attractive approach for the treatment of human cancer.

1 December 2001 in Laboratory Investigation
Verified
Journal Article
Closed access
SCSusanna Castel
Susanna Castel
RPRoser Pagan
Roser Pagan
Francesc MitjansFrancesc Mitjans
Francesc Mitjans
JPJaume Piulats
Jaume Piulats
SGSimon Goodman
Simon Goodman
MPManuel Reina del Pozo
Manuel Reina del Pozo

1 May 2005 in European Journal of Cancer
Verified
Journal Article
Closed access
AEAndreas Enns
Andreas Enns
TKTimo Korb
Timo Korb
KSKerstin Schlüter
Kerstin Schlüter
PGPeter Gassmann
Peter Gassmann
HSHans-Ullrich Spiegel
Hans-Ullrich Spiegel
Jörg HaierJörg Haier
Jörg Haier

17 March 2014 in Oncogenesis
Verified
Journal Article
Open access
PDF file
SDS Dakhel
S Dakhel
LPL Padilla
L Padilla
JAJ Adan
J Adan
MMM Masa
M Masa
JMJ M Martinez
J M Martinez
JHJ L Hernández
J L Hernández
Despite progresses in diagnosis and treatment, pancreatic cancer continues to have the worst prognosis of all solid malignant tumors. Recent evidences suggest that the metastasis-promoting protein S100P stimulates pancreatic tumor proliferation, survival, invasion and metastasis progression through extracellular functions. Moreover, its expression is strongly correlated with poor prognosis in patients with several types of cancer although the entire molecular mechanism responsible for the diverse biological functions is not fully understood. We showed that extracellular S100P stimulates pancreatic carcinoma BxPC3 cell line by promoting cell proliferation. We also demonstrated that S100P induces, in this cell line, the phosphorylation of IκBα and the secretion of matrix metalloproteinase 9 (MMP-9). In addition, treatment with S100P protected cells from injuries induced by the cytotoxic agent Gemcitabine. On the basis of these results, we developed function-blocking anti-S100P monoclonal antibodies (mAbs) that abolished all of its in vitro activities. Furthermore, in vivo treatment with the candidate 2H8 antibody decreased tumor growth and liver metastasis formation in a subcutaneous and orthotopic BxPC3 tumor model. We conclude here that a therapeutic strategy blocking the extracellular activity of S100P by means of specific mAbs could be an attractive therapeutic approach as a single agent or in combination with target-directed or chemotherapeutic drugs to treat pancreatic cancer.

1 April 2004 in Oligonucleotides
Verified
Journal Article
Closed access
SCSílvia Coma
Sílvia Coma
VNVeronique Noe
Veronique Noe
CLCinzia Lavarino
Cinzia Lavarino
JAJaume Adán
Jaume Adán
MRManuel Rivas
Manuel Rivas
Carlos CiudadCarlos Ciudad
Carlos Ciudad
The antiapoptotic protein survivin is an attractive target in cancer therapy because it is expressed differently in tumors and normal tissues and it is potentially required for cancer cells to remain viable. Given that survivin is also overexpressed in endothelial cells (ECs) of newly formed blood vessels found in tumors, its RNA targeting might compromise EC viability and interfere with tumor angiogenesis. We used two antisense strategies against survivin expression, antisense oligonucleotides (aODN) and small interfering RNA (siRNA), to study in ECs the contribution of survivin in various steps leading to tumor angiogenesis. A 21-mer phosphorothioate aODN and two siRNA oligonucleotides against survivin mRNA were designed to downregulate survivin expression. Survivin targeting caused (1) a strong growth-inhibitory effect, (2) a 4-fold increase in apoptosis, (3) an accumulation of cells in the S phase and a decrease in G2/M phase, (4) a dose-dependent inhibition of EC migration on Vitronectin, and (5) a decrease in capillary formation. Control oligonucleotides, an unrelated oligonucleotide, and one with four mismatches, had no significant effect. All these results show that survivin is a suitable target in cancer therapy because its inhibition in EC causes both a proapoptotic effect and an interruption of tumor angiogenesis. The two strategies used, classic aODN and siRNA technology, were very effective. Moreover, the latter can be used in the low nanomolar range, thus increasing the sensitivity of the treatment.

21 August 2017 in Oncogene
Verified
Journal Article
Closed access
PDF file
LPL Padilla
L Padilla
SDS Dakhel
S Dakhel
JAJ Adan
J Adan
MMM Masa
M Masa
JMJ M Martinez
J M Martinez
JHJ L Hernandez
J L Hernandez